U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07289776) titled 'A First-in-human Trial of GRT7041 in Healthy Participants' on Nov. 24.
Brief Summary: The purpose of this trial is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GRT7041 in healthy male and female (Women of non-childbearing potential) participants.
The trial duration will be up to approximately 6 weeks for participants in Part 1 (Single ascending dose [SAD]), except for participants taking part in the food effect cohort SAD3 where the trial duration will be up to approximately 8 weeks. The trial duration will be up to approximately 7 weeks in Part 2 (Multiple ascending dose [MAD]), and the Tr...